Anderson Karen M. 4

4 · Centessa Pharmaceuticals plc · Filed Mar 18, 2026

AI-generated summary of this filing

Updated Mar 18, 2026

Centessa (CNTA) CPO Karen Anderson Sells Shares After Exercising Options

What Happened

Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals plc (CNTA), exercised stock options and immediately sold the resulting shares. She exercised 74,811 shares (64,768 on 2026-03-16 and 10,043 on 2026-03-17) at an exercise price of $4.01 per share (total exercise cost $299,992). She sold those shares in open-market transactions for total gross proceeds of approximately $2,109,179 (64,768 shares at a $28.21 weighted average on 3/16; 10,043 shares at a $28.10 weighted average on 3/17).
Transaction codes: M = exercise/conversion of derivative (options), S = sale. The filing shows both the option conversion and the subsequent share sales.

Key Details

Transaction dates: March 16, 2026 (64,768 shares) and March 17, 2026 (10,043 shares).
Exercise cost: $4.01 per share; Sales weighted-average prices: $28.21 (3/16) and $28.10 (3/17).
Gross proceeds from sales: $1,826,969 (3/16) + $282,210 (3/17) = $2,109,179; total exercise cost ≈ $299,992.
Footnotes: Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted Nov 12, 2025 (F2). Reported sale prices are weighted averages; price ranges were $27.99–$28.41 (F3) and $27.99–$28.21 (F4). Ordinary shares may be represented by ADSs (F1). Vesting schedule for the option is noted in the filing (25% on Dec 1, 2023; remainder monthly over 36 months) (F5).
Shares owned after the transactions are not specified in the provided filing excerpt.
Filing: Form 4 filed Mar 18, 2026 for transactions on Mar 16–17, 2026 — appears to be a timely filing.

Context

This was an exercise of stock options followed by immediate open‑market sales of the acquired shares — a common pattern for exercising options and realizing value (sometimes called a cashless exercise or sell‑to‑cover when done same day). Such transactions provide liquidity and do not, by themselves, indicate the insider’s view of the company’s long‑term prospects.
The sales were executed under a pre-established 10b5‑1 plan, which typically schedules trades in advance and can limit concerns about opportunistic timing.

Form 4

Period: 2026-03-16

Chief People Officer

Transactions

Exercise/Conversion
Ordinary Shares
[F1]
2026-03-16$4.01/sh+64,768$259,720→ 126,853 total
Sale
Ordinary Shares
[F1][F2][F3]
2026-03-16$28.21/sh−64,768$1,826,969→ 62,085 total
Exercise/Conversion
Ordinary Shares
[F1]
2026-03-17$4.01/sh+10,043$40,272→ 72,128 total
Sale
Ordinary Shares
[F1][F2][F4]
2026-03-17$28.10/sh−10,043$282,210→ 62,085 total
Exercise/Conversion
Share Option (right to buy)
[F5][F1]
2026-03-16−64,768→ 85,043 total
Exercise: $4.01Exp: 2032-12-01→ Ordinary Shares (64,768 underlying)
Exercise/Conversion
Share Option (right to buy)
[F5][F1]
2026-03-17−10,043→ 75,000 total
Exercise: $4.01Exp: 2032-12-01→ Ordinary Shares (10,043 underlying)

Footnotes (5)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.99 to $28.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.99 to $28.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F5]25% of the shares subject to such option shall vest and become exercisable on December 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

Signature

/s/ Raphael Deferiere, attorney-in-fact|2026-03-18

1 file